Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592356 | 0.91 | EPHX2 (0.34) | CNR2PDK2PDK4CYP3A4CNR1 | |
| SCHEMBL4591651 | 0.90 | CNR2 (0.41) | CNR2PDK2PDK4CYP3A4BCL2A1 | |
| SCHEMBL4592793 | 0.89 | PDK1 (0.33) | CNR2PDK2PDK4CNR1THRB | |
| SCHEMBL4592432 | 0.89 | GCGR (0.38) | CNR2PDK2PDK4CYP3A4BCL2A1 | |
| SCHEMBL4592465 | 0.88 | PDK2 (0.41) | CNR2PDK2PDK4CYP3A4BCL2A1 | |
| SCHEMBL4592328 | 0.88 | PDK1 (0.33) | PDK2PDK4THRBMAPTPDK1 | |
| SCHEMBL4592510 | 0.87 | CYP3A4 (0.39) | CNR2PDK2PDK4CYP3A4BCL2A1 | |
| SCHEMBL4592378 | 0.87 | CNR2 (0.39) | CNR2PDK2PDK4CYP3A4BCL2A1 | |
| SCHEMBL9982664 | 0.86 | PDK2 (0.34) | CNR2PDK2PDK4PDK1 | |
| SCHEMBL4592578 | 0.86 | MAPT (0.38) | CNR2PDK2PDK4CYP3A4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | claimed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | claimed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1739078-A1 | Antagonists of C5a-receptor | Jerini AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220003-A1 | C5a Receptor Antagonists | C3AR1, C5AR2, C5AR1 | CNR2 14/4885PDK2 4759/4885PDK4 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.